Interleukin-7 Mediates Selective Expansion of Tumor-redirection Cytotoxic T Lymphocytes (CTLs) without Enhancement of Regulatory T-cell Inhibition

Serena K. Perna1, Daria Pagliara1,5, Aruna Mahendravada1, Hao Liu1, Malcolm K. Brenner1,2,4, Barbara Savoldo1,2, and Gianpietro Dotti1,3,4

Abstract

Purpose: The antitumor activity of chimeric antigen receptor (CAR)--redirected CTLs should be enhanced if it were possible to increase their proliferation and function after adoptive transfer without concomitantly increasing the proliferation and function of regulatory T cells (Treg). Here, we explored whether the lack of IL-7Rα in Treg can be exploited by the targeted manipulation of the interleukin-7 (IL-7) cytokine–cytokine receptor axis in CAR-engrafted Epstein–Barr Virus–specific CTLs (EBV-CTLs) to selectively augment their growth and antitumor activity even in the presence of Treg.

Experimental Design: We generated a bicistronic retroviral vector encoding a GD2-specific CAR and the IL-7Rα subunit, expressed the genes in EBV-CTLs, and assessed their capacity to control tumor growth in the presence of Treg in vitro and in vivo when exposed to either interleukin-2 (IL-2) or IL-7 in a neuroblastoma xenograft.

Results: We found that IL-7, in sharp contrast with IL-2, supports the proliferation and antitumor activity of IL-7Rα.CAR-GD2+ EBV-CTLs both in vitro and in vivo even in the presence of fully functional Treg.

Conclusions: IL-7 selectively favors the survival, proliferation, and effector function of IL-7Rα-transgenic/CAR-redirected EBV-CTLs in the presence of Treg both in vitro and in vivo. Thus, IL-7 can have a significant impact in sustaining expansion and persistence of adoptively CAR-redirected CTLs. Clin Cancer Res; 20(1); 131–9. ©2013 AACR.

Introduction

The expression of chimeric antigen receptors (CAR) in T lymphocytes to redirect their antigen specificity has significantly expanded the clinical application of adoptive T-cell immunotherapies against a variety of human malignancies (1, 2). CAR molecules are chimeric proteins, in which a single chain antibody-binding site is fused with the signaling domain CD3ζ that activates T lymphocytes upon binding to the tumor antigen (3). However, in this form, CAR molecules do not provide adequate costimulation to T cells (1, 4, 5). To overcome this limitation, CARs can be expressed by CTLs whose native receptors are specific for virus latency proteins such as those derived from the Epstein–Barr Virus–specific CTLs (EBV-CTLs; refs. 6, 7).

These virus-specific CTLs can receive physiologic costimulation from professional antigen presenting cells processing latent viral antigens and kill tumor cells through their CAR (6, 7). Although this approach can produce complete and sustained antitumor responses, for example in some patients with neuroblastoma, in most recipients, CAR-engrafted EBV-CTLs have limited in vivo survival and fail to consistently eradicate disease (8, 9). It is likely that the combination of host/tumor associated inhibitory factors and insufficient in vivo immunostimulation limit the expansion and persistence of these cells (10).

Regulatory T cells (Treg) play a significant role in impairing the antitumor effects of tumor-specific CTLs (11). Treg are frequently increased in the peripheral blood and in tumor biopsies of patients with cancer (12–17) and their presence often correlates with poor clinical outcome (15). Thus, the development of strategies aimed at eliminating Treg or at selectively favoring the expansion of antitumor CTLs may significantly contribute in enhancing the engagement and antitumor effects of adoptively transferred CTLs. To date, most efforts to increase in vivo immunostimulation of adoptively transferred T cells have focused on administration of interleukin (IL)-2 (18). Although this cytokine is a potent T-cell growth factor, it is not selective for effector T-cell subsets and can also enhance the growth and inhibitory activity of Treg (19).
Translational Relevance
Adoptive transfer of virus-specific CTLs expressing a chimeric antigen receptor (CAR) represents a promising therapy for patients with cancer. However, the in vivo expansion of these cells remains suboptimal so that new strategies are required to selectively expand them without favoring the concomitant proliferation and function of regulatory T cells (Treg) that are often abundant in patients with cancer. Our study provides preclinical data, indicating that the manipulation of the interleukin (IL)-7 cytokine–cytokine receptor axis in CAR-engrafted Epstein–Barr Virus–specific CTLs (EBV-CTLs) can be used to selectively expand the CTLs while avoiding the inhibitory effects of Treg, which would otherwise be enhanced by use of the more broadly acting T-cell growth factor IL-2.

One means by which T lymphocytes can be selectively expanded is by using IL-7, a y-chain cytokine that promotes homeostatic expansion of naive and memory T cells but has no activity on Treg, which lack the IL-7Rα (the private chain of the IL-7 receptor; refs. 20–23). Administration of recombinant IL-7 was well tolerated in early-phase clinical trials, and expanded naive and central-memory T-cell subsets but not Treg (20, 21). Unfortunately, under physiologic conditions, IL-7 cannot support the in vivo expansion of adoptively transferred CAR-redirected CTLs as this is an effectormemory T-cell subset that, like Treg, also lacks IL-7Rα (24).

Here, we developed models in vitro and in vivo to demonstrate that human Treg clearly inhibit the antitumor effects of CAR-redirected EBV-CTLs. We also show that selective modulation of the IL-7 cytokine–cytokine receptor axis in CAR-engrafted EBV-CTLs augments their antitumor effects in vivo in the presence of Treg. This strategy should safely enhance the persistence and survival of adoptively transferred CAR-redirected virus-specific CTLs in patients with cancer.

Materials and Methods
Plasmid construction, retrovirus production, and tumor cell lines
The full-length human IL-7Rα linked through the 2A (TAV) sequence to the CAR-GD2 encoding the CD28 endodomain (25) was cloned into the SFG retroviral vector to generate the bicistronic vector SFGILTAV. The retroviral vectors encoding eGFP and Firefly Luciferase (FFluc) were previously described (26). Retroviral supernatant was prepared using transient transfection of 293T cells (26). The neuroblastoma cell line CHLA-255 (ref. 27; kindly provided by Dr. Leonid Metelitsa, Texas Children’s Hospital, Baylor College of Medicine, Houston, TX) was derived from a patient, and we verified that this line retains the surface expression of the target antigen GD2.

Generation and transduction of EBV-CTLs
EBV-transformed lymphoblastoid cells (LCL) and EBV-CTLs were prepared using peripheral blood mononuclear cells (PBMC), obtained from healthy donors as previously described (28). EBV-CTLs were transduced with retroviral supernatant after three stimulations with autologous LCLs, as previously described (8), and then maintained in culture by weekly stimulation with LCLs and recombinant IL-2 (50 IU/mL) or IL-7 (2.5 ng/mL; PeproTech).

Expansion of Treg
To obtain significant numbers of cells for the in vitro and in vivo experiments, Treg were isolated and expanded as previously described (29). Briefly, CD25bright T cells were purified from PBMCs by positive selection using immunomagnetic separation in the presence of nonsaturating concentrations (2 mL/1 × 10⁷ PBMCs) of anti-human CD25 magnetic beads (Miltenyi Biotech). On day 0, the purified CD25+ T cells were activated in 24-well plates coated with OKT3 (1 µg/mL) and anti-CD28 antibody (BD Pharminogen; 1 µg/mL) in RPMI 1640 in the presence of rapamycin (Sigma) at a final concentration of 100 nmol/L. On days 7 and 14, cells were restimulated with OKT3/CD28 antibodies, irradiated feeder cells, rapamycin, and IL-2 (50 IU/mL) in small bioreactors (G-REX; ref. 29). At the end of the 3-week culture (day 21), cells were used for in vitro and in vivo experiments. The cell fraction obtained from buffy coats after the selection of CD25bright T cells was further enriched for CD4+ cells which were then used as negative control in parallel culture experiments, in which we evaluated the immunosuppressive activity of Treg (29, 30).

Immunophenotyping
Cells were stained with fluorescein isothiocyanate (FITC)-, phycoerythrin (PE)-, peridinin-chlorophyll-protein complex (PerCP)-, or allophycocyanin (APC)-conjugated monoclonal antibodies (mAb). We used CD3, CD4, CD8, CD25, and CD127 (IL-7Rα specific) from Becton Dickinson (BD Bioscience) and FoxP3 from eBioscience Inc. CAR-GD2 expression by transduced EBV-CTLs was detected using the specific anti-idiotype antibody 1A7, followed by staining with the secondary antibody RAM-IgG1-PE (Becton Dickinson; ref. 8). STAT5 phosphorylation in Treg and EBV-CTLs was assessed after cytokine stimulation for 15 minutes using the anti-phospho-STAT5 (Y694) mAb-Alexa Fluor 647 Conjugate (BD Phosphor Reagents). Cells were analyzed using a BD FACS Calibur system equipped with the filter set for quadruple fluorescence signals and the CellQuest software (BD Biosciences). For each sample, we analyzed a minimum of 10,000 events.

Carboxyfluorescein diacetate succinimidyl ester–based assays
Proliferation of Treg or EBV-CTLs or activated PBMC was assessed by carboxyfluorescein diacetate succinimidyl ester (CFSE) dilution. Briefly, EBV-CTLs were labeled with 1.5 µmol/L CFSE (Invitrogen) and activated with LCLs (ratio 4:1) with or without IL-2 (12.5 IU/mL) or IL-7 (10 ng/mL). CFSE dilution was measured by flow cytometry after 7 days of culture. A similar protocol was used to evaluate the proliferation of CFSE-labeled Treg post activation with
OKT3, irradiated feeders, and IL-2 or IL-7. To evaluate the suppressive activity of Treg, CFSE-labeled EBV-CTLs were stimulated with LCLs (ratio 4:1) in the presence of Treg or control CD4+ CD25+ cells (ratio, 1:1, ref. 30), and of IL-2 (12.5 IU/mL) or IL-7 (10 ng/mL). Similarly, PBMC depleted of CD25 bright cells were stained with CFSE and activated in the presence of irradiated allogeneic feeders (ratio 2:1) and OKT3 (500 ng/mL; refs. 29, 30). After 7 days, cells were stained with CD8-APC and CD4-PerCP, analyzed by fluorescence-activated cell sorting (FACS) and cell division assessed by CFSE dilution.

Evaluation of antitumor activity

EBV-CTLs were cultured in the presence of the neuroblastoma cell line (CHLA-255) genetically modified to stably express GFP in the presence or in the absence of Treg (at the EBV-CTLs:CHLA-255:Treg ratio of 1:2:1) and of IL-2 (12.5 IU/mL) or IL-7 (5 ng/mL). After 7 days, cells were collected, stained with CD3 to identify T cells, and analyzed by FACS. GFP was used to quantify residual tumor cells in culture.

Xenogenic mouse model

To assess the antitumor effect of EBV-CTLs in vivo in the presence of Treg, we used the xenograft mouse model and an in vitro imaging system as previously described (7, 24). Mouse experiments were performed in accordance with Baylor College of Medicine’s Animal Husbandry guidelines. Briefly, 8- to 10-week-old NOD.Cg-Pkdscid IL2tgMMont/ljSz (NSG) mice (Jackson Laboratory, Bar Harbor, ME) were engrafted intraperitoneally with the CHLA-255 cells (1 × 10⁶ cells per mouse) genetically modified with FFluc to monitor tumor growth using the IVIS bioluminescence system (Xenogen IVIS 200 Biophotonic Imaging System). The intraperitoneal model was selected to minimize confounding issues due to suboptimal cell biodistribution and simultaneous colocalization at the tumor site of CAR-modified EBV-CTLs and Treg. When the signal [measured as p/sec/cm²/sr] was consistently increasing, usually by day 7 to 10, mice received intraperitoneal EBV-CTLs (10 × 10⁶ T cells per mouse) with or without Treg (10 × 10⁶ T cells per mouse; two infusions 1-week apart). IL-2 (500 IU/mouse) or IL-7 (200 ng/mouse) were administered intraperitoneally three times a week.

Statistical analysis

All in vitro data were summarized by means and SEM. For the bioluminescent experiments, intensity signals were log-transformed and summarized using mean ± SD at baseline and multiple subsequent time points for each group of mice. Changes in intensity of signal from baseline at each time point were calculated and compared using paired t tests or Wilcoxon signed-ranks test. When the P value was less than 0.05, a mean difference was accepted as statistically significant. For the bioluminescence experiments, intensity signals were log-transformed and summarized using mean and SDs at baseline and multiple subsequent time points for each group of mice. The response profiles over time were analyzed by the generalized estimating equations method for repeated measurements.

Results

Functional IL-7Rα and CAR-GD2 can be coexpressed in EBV-CTLs

To restore the responsiveness to IL-7 and to redirect the antigen specificity of EBV-CTLs against neuroblastoma, we generated a bicistronic γ-retroviral vector encoding the IL-7Rα and a GD2-specific CAR linked through a 2A (TAV) sequence (SFG.IL-7Rα.2A.CAR-GD2; Fig. 1A). EBV-CTLs established from 5 healthy EBV-seropositive donors were transduced with the vector, and the expression of both IL-7Rα and CAR-GD2 was measured by FACS analysis. As shown in Figure 1B, both CAR-GD2 and IL-7Rα were stably expressed (64% ± 3% and 34% ± 9%, respectively) in transduced EBV-CTLs, whereas the expression of the native IL-7Rα on control cells remained negligible (4% ± 1%).

To evaluate the functionality of the transgenic IL-7Rα, we measured the phosphorylation of STAT5 in response to either IL-2 or IL-7. In the absence of cytokines, control and IL-7Rα-CAR-GD2 EBV-CTLs showed negligible phosphorylation of STAT5 (3% ± 2% and 8% ± 4%, respectively). In IL-7Rα-CAR-GD2 EBV-CTLs, near equal STAT5 phosphorylation of Tyr-694 was detected in response to IL-2 (49% ± 7%) or IL-7 (38% ± 6%, respectively; P = NS). In contrast, in control cells, STAT5 was phosphorylated in response to IL-2 (63% ± 8%) but not to IL-7 (6% ± 5%, P < 0.05; Fig. 1C). The levels of IL-7Rα–dependent STAT5 phosphorylation in IL-7Rα-CAR-GD2 EBV-CTLs exposed to IL-7 were very similar to the amount observed in T lymphocytes physiologically expressing the IL-7Rα and exposed to IL-7 (Supplementary Fig. S1A). The functionality of the transgenic IL-7Rα was further supported by progressive selection of transgenic cells if cultures were supplemented with IL-7. As illustrated in Figure 1D (and Supplementary Fig. S1B), when IL-7Rα-CAR-GD2 CTLs were stimulated weekly with autologous LCLs and IL-7, the expression of both IL-7Rα and CAR-GD2 progressively increased between the third and sixth antigen-specific stimulation (from 34% ± 9% to 66% ± 5% for IL-7Rα, and from 64% ± 3% to 80% ± 7% for CAR-GD2). In contrast, when CTLs were expanded in the presence of IL-2, no enrichment of either transgenes was observed, as this cytokine equally supports the ex vivo growth of transduced and non transduced CTLs (data not shown).

The enrichment of transgenic T cells following exposure to IL-7 was a consequence of the proliferation of IL-7Rα-CAR-GD2 EBV-CTLs. As illustrated in Figure 2A, CFSE labeled-control and IL-7Rα-CAR-GD2 EBV-CTLs divided equally well when stimulated with LCLs (ratio 4:1) in the presence of IL-2 (proliferation, 68% ± 6% and 68% ± 4%, respectively). In contrast, in the presence of IL-7, IL-7Rα-CAR-GD2 but not control EBV-CTLs had significantly greater proliferation, 63% ± 3% versus 14% ± 1%, respectively (P < 0.001). The number of EBV-CTLs proliferating in response to EBV-LCLs and IL-7 was generally higher than expected based on the ectopic expression of IL-7Rα. This higher level is likely a consequence of the physiologic production of IL-2 by EBV-CTLs in response to their cognate EBV antigens (EBV-LCLs; Supplementary Fig. S2). Finally,
exposure of IL-7Rα.CAR-GD2+ EBV-CTLs to IL-7 did not affect their antitumor properties. As shown in Figure 2B, when EBV-CTLs were cultured with CHLA-255 cells, only IL-7Rα.CAR-GD2+ cells controlled tumor growth in the presence of either IL-2 or IL-7 (6% ± 1% and 4% ± 1%, respectively), whereas tumor cells outgrew in cultures containing control EBV-CTLs irrespective of the cytokine added (43% ± 5% and 57% ± 12%, respectively; P < 0.001).

**Ex vivo expanded Treg do not respond to IL-7**

We used *ex vivo* expanded CD4+ CD25+ Treg isolated from healthy donors rather than freshly isolated Treg for the following reasons. First, the experiments required a significant number of Treg that could not be obtained upon fresh isolation even from buffy coat preparations. Second, circulating Treg obtained after immunomagnetic selection on the basis of CD4 and CD25 expression are frequently contaminated by CD4+ CD25+ IL7Rα+ cells that lack regulatory activity, but respond to IL-7 (data not shown; ref. 31). We first confirmed that the nominal Treg population retained their inhibitory properties. As shown in Figure 3A, the proliferation of activated PBMCs (80% ± 3% in the presence of control CD4+ CD25+ cells) was significantly inhibited in the presence of the expanded Treg population (27% ± 6%; P < 0.001). We then confirmed that these Treg, like freshly isolated Treg (22), lacked expression of IL-7Rα (3% ± 0.4% positive; Fig. 3B). As a consequence, STAT5 was only phosphorylated in these Treg in response to IL-2 (MFI = 75 ± 9; P < 0.001) and not in response to IL-7 (MFI = 23 ± 3; Fig. 3C).
Finally, a CFSE-based dilution assay showed that Treg only proliferated after polyclonal activation in the presence of IL-2 and not on exposure to IL-7 (MFI 1439 ± 207 vs. 445 ± 68, respectively; P < 0.001; Fig. 3D).

**IL-7 supports the proliferation and effector function of IL-7Rα.CAR-GD2⁺ EBV-CTLs in the presence of Treg**

Having demonstrated that IL-7 supports the proliferation and function of IL-7Rα.CAR-GD2⁺ EBV-CTLs, we then investigated whether the beneficial effects of IL-7 were maintained in the presence of functional Treg. As illustrated in Figure 4A, when IL-7Rα.CAR-GD2⁺ EBV-CTLs were cultured with CHLA-255 GFP-tagged tumor cells (at ratio 1:2) in the presence of IL-2 or IL-7. Residual tumor cells were enumerated by flow cytometry on day 7 of culture. The graph shows mean ± SD of five independent experiments. *, P < 0.001.

IL-7 Overcomes Treg inhibition of CAR-modified CTLs

Figure 2. IL-7 supports the proliferation and effector function of IL-7Rα.CAR-GD2⁺ EBV-CTLs. A, representative CFSE-based proliferation assay of control and IL-7Rα.CAR-GD2⁺ EBV-CTLs. Control and IL-7Rα.CAR-GD2⁺ EBV-CTLs were activated in the presence of autologous irradiated LCLs and either IL-2 or IL-7. CFSE dilution was evaluated on day 7 using FACS analysis. The graph represents mean ± SD of five independent experiments. B, representative coculture experiment in which control and IL-7Rα.CAR-GD2⁺ EBV-CTLs were cocultured with CHLA-255 GFP-tagged tumor cells (at ratio 1:2) in the presence of IL-2 or IL-7. Residual tumor cells were enumerated by flow cytometry on day 7 of culture. The graph shows mean ± SD of five independent experiments. *, P < 0.001.

IL-7 supports the in vivo antitumor activity of IL-7Rα.CAR-GD2⁺ EBV-CTLs even in the presence of Treg

To assess the in vivo capacity of IL-7 to support the antitumor activity of IL-7Rα.CAR-GD2⁺ EBV-CTLs, we used NSG mice engrafted intraperitoneally with the FFLuc cell line CHLA-255. As shown in Figure 5, control mice that received only tumor cells or control CTLs showed a rapid
increase of the bioluminescence signal ($2.3 \times 10^8 \pm 3 \times 10^7$ photons) and were sacrificed by day 18. Mice infused with IL-7Rα.CAR-GD2+ EBV-CTLs and IL-2 had superior tumor control ($1.6 \times 10^8 \pm 2 \times 10^7$ photons at day 34), but this effect was abrogated when Treg were coinfused ($2.4 \times 10^8 \pm 4 \times 10^7$ photons at day 34; $P < 0.05$). In contrast, mice infused with IL-7Rα.CAR-GD2+ EBV-CTLs and IL-7 controlled tumor growth equally well in the absence ($1.2 \times 10^8 \pm 3 \times 10^7$ photons) or in presence of Treg ($1.3 \times 10^8 \pm 6 \times 10^7$ photons) at day 34.

Discussion

The adoptive transfer of CAR-redirected EBV-CTLs safely induces tumor regression in patients with neuroblastoma and the approach is potentially applicable to other human malignancies (8, 9). To further improve the clinical benefits of this approach, we developed a strategy that selectively promotes the in vivo expansion of CAR-redirected CTLs without favoring the proliferation and function of Treg that may limit long-term persistence and activity of the infused effector cells and thereby compromise antitumor efficacy. Here, we demonstrate that CAR-redirected EBV-CTLs engineered to regain responsiveness to IL-7 by restoring their expression of IL-7Rα proliferate in response to a combination of native T-cell receptor (TCR) and IL-7 stimulation without favoring the expansion and function of Treg. As a consequence, we observed an increase in their CAR-mediated antineuroblastoma activity, even in the presence of Treg.

Successful clinical outcome following adoptive transfer of tumor-specific T cells strongly correlates with the in vivo survival and proliferation of these cells (18, 32, 33). In addition to the intrinsic properties of T lymphocytes, such as central-memory versus effector-memory versus naïve phenotype that directly dictate the self-maintenance capacity of tumor-specific T cells (34), several tumor-associated mechanisms are also pivotal in determining the consequences of administering tumor-specific T cells (10, 35). Treg in particular are abundant in the tumor microenvironment and are a major factor in impairing T-cell function. Hence, strategies that selectively increase persistence and expansion of adoptively transferred T cells or that eliminate the influence of this cell subset should be as relevant for T-cell therapies as they have proved to be for cancer-vaccine trials (36).

The administration of recombinant cytokines or the use of cytokine-engineered T cells (30, 37, 38) that selectively support T-cell growth without providing functional or proliferative advantages to Treg represent appealing approaches to overcome the inhibitory function of Treg within the tumor microenvironment. However, IL-2 that is frequently used to sustain the in vivo proliferation and persistence of adoptively transferred CTLs is nonspecific, stimulating both tumor-specific effector T cells and Treg, as both these cell
subsets express the IL-2 high affinity receptor (CD25; refs. 19, 39). Thus, as illustrated in the current and prior studies, the net effect of IL-2 administration is to block the proliferation and antitumor effects of CAR-redirected CTLs both in vitro and in vivo.

Although IL-7 shares several functions with IL-2, it also has effects on specific T-cell subsets that depend on their expression of the private IL-7Rα subunit (23). Our experiments demonstrate both in vitro and in vivo that IL-7 can nonetheless support the survival, expansion, and effector function of CAR-redirected EBV-CTLs if these cells are engineered to reexpress the IL-7Rα and thereby overcome the inhibitory effects of Treg. Our approach has significant advantages over the use of IL-2 or cytotoxic drugs to eliminate Treg in a nonselective manner (40) as it may promote the long-term persistence of CAR-redirected EBV-CTLs both in steady-state conditions and in a lymphopenic environment (23). In addition, the administration of recombinant IL-7 unlike recombinant IL-2 seems to be well tolerated even at high doses (20, 21, 41). Finally, as

![Figure 4](https://example.com/figure4.png)

Figure 4. IL-7, unlike IL-2, supports in vitro the proliferation and function of IL-7Rx.CAR-GD2 EBV-CTLs in the presence of Treg. A, IL-7Rx.CAR-GD2 EBV-CTLs were cocultured with CHLA-255 GFP-tagged cells (ratio 1:2) in the presence of IL-2 or IL-7, with or without Treg. The percentage of residual tumor cells was measured by flow cytometry on day 7 of culture. The plots on the left show a representative experiment, whereas the graph on the right summarizes mean ± SD of five independent experiments. B, IL-7Rx.CAR-GD2 EBV-CTLs were labeled with CFSE and activated with autologous LCLs in the presence of IL-2 (top) or IL-7 (bottom) with or without Treg. CFSE dilution was measured at day 7 of culture by flow cytometry. The plots on the left show a representative experiment, whereas the graph represents mean ± SD of five independent experiments. *, P < 0.01; **, P = 0.005.

![Figure 5](https://example.com/figure5.png)

Figure 5. IL-7, but not IL-2, supports in vivo antitumor activity of IL-7Rx.CAR-GD2 EBV-CTLs in the presence of Treg. NSG mice engrafted intraperitoneally with CHLA-255 cells tagged with FFLuc were infused with IL-7Rx.CAR-GD2 EBV-CTLs and received IL-2 ± Treg or IL-7 ± Treg. Tumor growth was monitored using an in vivo imaging system (Xenogen IVIS imaging system). A group of mice received control EBV-CTLs or tumor cells only (Control). A, images of different groups of mice. B, mean ± SD of photons for 8 mice/group in two independent experiments. *, P < 0.05.
the infusion of virus-specific CTLs after allogeneic stem-cell transplant does not induce the occurrence of graft versus host disease (28), our proposed approach of infusing CARredirected CTLs with restored responsiveness to the homeostatic cytokine IL-7 may significantly increase the application of CAR technology in the allogeneic setting (42).

One potential concern associated with any genetic manipulation of T cells is that the cells will undergo malignant transformation, or grow in an antigen independent manner. This concern is particularly prominent when the genetic manipulation modifies a growth factor receptor or other portions of a signaling pathway. However, the experience of our own and other groups has been that the genetic manipulation of differentiated T cells to express cytokines or cytokine receptors does not affect the antigen specificity of these cells and does not elicit uncontrolled proliferation (24, 37, 43). These results were confirmed in the current study even if we cannot completely exclude the possibility of secondary paracrine effects due to the ectopic expression of IL-7Rα. If such a concern remains, however, incorporation of suicide or safety switches within the cells may provide a further level of reassurance (37, 44).

Our study suggests that restoring the responsiveness to IL-7 of virus-specific CTLs redirected with a CAR is a strategy that may allow enhanced T-effector cells without concomitant inhibition by Treg and may thereby further improve the clinical outcome of a promising therapeutic approach.

Disclosure of Potential Conflicts of Interest

M.K. Brenner is a consultant/advisory board member of Bluebird Bio. The Center for Cell and Gene Therapy has a research collaboration with Celgene and Bluebird Bio. G.D. BS and MKB have patent applications in the field of T cell and gene-modified T-cell therapy for cancer. No potential conflicts of interest were disclosed by the other authors.

Authors’ Contributions

Conception and design: S.K. Perna, M.K. Brenner, B. Savoldo, G. Dotti

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): S.K. Perna, D. Pagliara, B. Savoldo, G. Dotti

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): S.K. Perna, D. Pagliara, H. Liu, B. Savoldo, G. Dotti

Writing, review, and/or revision of the manuscript: S.K. Perna, M.K. Brenner, B. Savoldo, G. Dotti

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): S.K. Perna, M.K. Brenner

Study supervision: B. Savoldo, G. Dotti

Provided technical assistance for some of the in vitro and in vivo experiments: A. Mahendravada

Grant Support

This work was supported in part by R01 CA142636 NIH-NCI, W81XWH10-10425 Department of Defense, Technology/Therapeutic Development Award.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received April 12, 2013; revised September 20, 2013; accepted September 26, 2013; published OnlineFirst October 4, 2013.

References


Correction: Interleukin-7 Mediates Selective Expansion of Tumor-Redirected Cytotoxic T Lymphocytes (CTLs) without Enhancement of Regulatory T-Cell Inhibition

In this article (Clin Cancer Res 2014;20:131–9), which was published in the January 1, 2014, issue of Clinical Cancer Research (1), a section of the grant support was mistakenly omitted. It should read as follows: “This work was supported in part by R01 CA142636 NIH-NCI, W81XWH-10-10425 Department of Defense, Technology/Therapeutic Development Award, and by P50CA126752 SPORE in Lymphoma from NCI.” The authors regret this error.

Reference


Published online August 14, 2014.
doi: 10.1158/1078-0432.CCR-14-1550
©2014 American Association for Cancer Research.
Interleukin-7 Mediates Selective Expansion of Tumor-redirection Cytotoxic T Lymphocytes (CTLs) without Enhancement of Regulatory T-cell Inhibition

Serena K. Perna, Daria Pagliara, Aruna Mahendravada, et al.


Updated version
Access the most recent version of this article at: doi:10.1158/1078-0432.CCR-13-1016

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2013/10/04/1078-0432.CCR-13-1016.DC1

Cited articles
This article cites 44 articles, 26 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/20/1/131.full.html#ref-list-1

Citing articles
This article has been cited by 5 HighWire-hosted articles. Access the articles at:
/content/20/1/131.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.